Derek W Bartlett
Overview
Explore the profile of Derek W Bartlett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
OBrien Laramy M, Luthra S, Brown M, Bartlett D
Nat Rev Drug Discov
. 2023 Feb;
22(5):410-427.
PMID: 36810917
Over the past 3 years, the first bivalent protein degraders intentionally designed for targeted protein degradation (TPD) have advanced to clinical trials, with an initial focus on established targets. Most...
2.
Bartlett D, Gilbert A
Chem Soc Rev
. 2022 Apr;
51(9):3477-3486.
PMID: 35438107
Targeted protein degradation has emerged from the chemical biology toolbox as one of the most exciting areas for novel therapeutic development across the pharmaceutical industry. The ability to induce the...
3.
Bartlett D, Gilbert A
J Pharmacokinet Pharmacodyn
. 2020 Oct;
48(1):149-163.
PMID: 33090299
Bispecific protein degraders (BPDs) engage the ubiquitin-proteasome system (UPS) to catalytically degrade intracellular proteins through the formation of ternary complexes with the target protein and E3 ubiquitin ligases. Here, we...
4.
Guerrero Y, Desai D, Sullivan C, Kindt E, Spilker M, Maurer T, et al.
AAPS J
. 2020 Mar;
22(2):53.
PMID: 32124093
Static in vitro cell culture studies cannot capture the dynamic concentration profiles of drugs, nutrients, and other factors that cells experience in physiological systems. This limits the confidence in the...
5.
Bartlett D, Wu A, Li X, Kraus M, Wang H, Kindt E
J Pharm Sci
. 2019 May;
108(9):3124-3129.
PMID: 31136767
Microdialysis is a technique that utilizes a semipermeable membrane to sample analytes present within tissue interstitial fluid. Analyte-specific calibration is required for quantitative microdialysis, but these calibration methods are tedious,...
6.
Affolter T, Llewellyn H, Bartlett D, Zong Q, Xia S, Torti V, et al.
PLoS One
. 2019 May;
14(5):e0217276.
PMID: 31112568
Cancer cells harness immune checkpoints such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase 1 (IDO1) to evade immune control. Checkpoint inhibitors have...
7.
Ming J, Abrams R, Bartlett D, Tao M, Nguyen T, Surks H, et al.
Gene Regul Syst Bio
. 2017 Aug;
11:1177625017710941.
PMID: 28804243
Reduction in low-density lipoprotein cholesterol (LDL-C) is associated with decreased risk for cardiovascular disease. Alirocumab, an antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduces LDL-C. Here, we report...
8.
Viola-Villegas N, Sevak K, Carlin S, Doran M, Evans H, Bartlett D, et al.
Mol Pharm
. 2014 May;
11(11):3965-73.
PMID: 24779727
Engineered antibody fragments offer faster delivery with retained tumor specificity and rapid clearance from nontumor tissues. Here, we demonstrate that positron emission tomography (PET) based detection of prostate specific membrane...
9.
Sano K, Nakajima T, Ali T, Bartlett D, Wu A, Kim I, et al.
J Biomed Opt
. 2013 Jun;
18(10):101304.
PMID: 23752742
Antibody fragments including diabodies have more desirable pharmacokinetic characteristics than whole antibodies. An activatable optical imaging probe based on a cys-diabody targeting prostate-specific membrane antigen conjugated with the near-infrared fluorophore,...
10.
Bartlett D, Colcher D, Raubitschek A
Bioconjug Chem
. 2008 Aug;
19(9):1927-37.
PMID: 18720981
Increasing interest in the use of radiolabeled antibodies for cancer imaging and therapy drives the need for more efficient production of the antibody conjugates. Here, we illustrate a method for...